10:50 AM EST - BriaCell Therapeutics Corp. : Announces new positive Phase 2 survival data highlighting multiple patients surpassing expected benchmarks for metastatic breast cancer and survival length over 18 months in nine cases as of their last assessment. BriaCell Therapeutics Corp.
shares T.BCT are trading up $0.05 at $6.43.
